Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients —a perspective
The recent coronavirus disease 2019 (COVID-19) pandemic raises serious concerns about potential prophylaxis and therapy in a naive population, particularly in patients with primary or secondary immunodeficiencies. The former mainly includes patients with defects in T-cell –mediated immunity and, to a lesser extent, those with antibody deficiencies and immune dysregulation. The latter includes patients undergoing therapy with immunosuppressive drugs, such as stem cell transplanted patients. In addition, patients with B-cell malignancies and autoimmune disorders trea ted with selected forms of targeted therapy (such as anti-CD20) may develop secondary immunodeficiency characterized by hypogammaglobulinemia.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Lennart Hammarstr öm, Hassan Abolhassani, Fausto Baldanti, Harold Marcotte, Qiang Pan-Hammarström Tags: Editorial Source Type: research
More News: Allergy | Allergy & Immunology | Autoimmune Disease | Cancer & Oncology | Coronavirus | COVID-19 | Pandemics | SARS | Stem Cell Therapy | Stem Cells | Transplants